In February, I had the honor of assisting NIH Director Dr.
Francis Collins as he announced an unprecedented public health collaboration:
the Accelerating Medicines Partnership. As you can read more about in this
issue, NIH joined 10 pharmaceutical companies and nonprofit organizations to
tackle several public health issues, including type 2 diabetes, in innovative
To make this pilot project a success, we’ll be sharing our
unique expertise and resources. NIH
brings the power of our worldwide clinical consortiums and data. Industry
brings an extensive knowledge of how to identify viable drug targets and bring
them to market.
Working together, we hope to find targets likely to work in
diabetes treatment and prevention. I’m confident you’ll hear much more about
the fruits of this partnership in the years to come.
Though we work with others, we also take great pride in the
contributions of our staff and grantees as individuals, including NIDDK
intramural investigator Dr. Herbert Tabor, a prolific researcher and
“scientific grandfather” many times over.
In late 2013, Dr. Tabor celebrated 70 years of federal service – yes,
you read that seven-zero right!
President Barack Obama said it best in a letter to Dr. Tabor
thanking him for his service, saying: “Whether aboard a Coast Guard cutter or
hard at work at the National Institutes of Health, he has furthered scientific
knowledge and helped our Government fulfill its obligations to the American
Serving the American people by improving health through
biomedical research is our obligation, our goal and our passion. Through
projects like AMP and with the unwavering dedication of individuals like Herb
Tabor, we move ever closer to preventing, treating and curing some of the
world’s most devastating diseases.